US20050054735A1 - 6-Methoxy-2-naphthylacetic acid prodrugs - Google Patents

6-Methoxy-2-naphthylacetic acid prodrugs Download PDF

Info

Publication number
US20050054735A1
US20050054735A1 US10/970,571 US97057104A US2005054735A1 US 20050054735 A1 US20050054735 A1 US 20050054735A1 US 97057104 A US97057104 A US 97057104A US 2005054735 A1 US2005054735 A1 US 2005054735A1
Authority
US
United States
Prior art keywords
6mna
compound
acid
prodrugs
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/970,571
Inventor
Nnochiri Ekwuribe
Tatyana Dyakonov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Ekwuribe Nnochiri Nkem
Dyakonov Tatyana A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ekwuribe Nnochiri Nkem, Dyakonov Tatyana A. filed Critical Ekwuribe Nnochiri Nkem
Priority to US10/970,571 priority Critical patent/US20050054735A1/en
Publication of US20050054735A1 publication Critical patent/US20050054735A1/en
Assigned to NOBEX CORPORATION reassignment NOBEX CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EKWURIBE, NNOCHIRI N., DYAKONOV, TATYANA
Assigned to BIOCON LIMITED reassignment BIOCON LIMITED SECURITY AGREEMENT Assignors: NOBEX CORPORATION
Assigned to BIOCON LIMITED reassignment BIOCON LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOBEX CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to pharmaceutical compositions useful for treatment of inflammation in humans utilizing compounds that are prodrugs of 6-methoxy-2-naphthylacetic acid (hereinafter “6MNA”).
  • 6MNA 6-methoxy-2-naphthylacetic acid
  • Compound (I) can, however, cause severe irritation of the gastronintestinal tract at dosages only slightly greater than the excess of the therapeutic dose.
  • naphthalene derivative is nabumetone having the formula (II): as described in U.S. Pat. Nos. 4,061,779 and 4,420,639 to Lake et al.
  • Nabumetone works by inhibiting cyclooxygenase, an enzyme responsible for making prostaglandins which are mediators of inflammation.
  • Nabumetone is a prodrug which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid, Formula (III): (See Haddock, R. E. et al; Metabolism of Nabumetone (BRL 14777 by various species including man,” Xenobiotica; 14(4): 327-337 (1984)).
  • Nabumetone is commercially available as Relafen® from Smithkline Beecham, Inc. However, only about 35 percent of orally administered nabumetone is transferred in vivo into 6MNA.
  • Another concern with 6MNA and its related prodrugs is that the presence of the carboxylic acid moiety can cause stomach irritation and/or ulceration.
  • the present invention provides therapeutically effective amounts of 6MNA prodrugs. It is believed that the 6MNA prodrug of the invention has improved hydrolysis and solubility. It is believed that the prodrugs of the invention are useful for the treatment of inflammation in humans, and can provide analgesic and antipyretic properties.
  • the pharmaceutical composition comprises wherein R is selected from the group consisting of H and COR′, wherein R′ is selected from the group consisting of C 1 to C 6 alkyl, (CH 2 ) m O(CH 2 ) n , (CH 2 ) m (OC 2 H 4 ) p O(CH 2 ) n , (CH 2 ) m (OC 2 H 4 ) p , (OCH 2 H 4 ) p ONO 2 and (OCH 2 H 4 ) p O(CH 2 ) n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4.
  • R is a therapeutic moiety.
  • FIG. 1 is a graph of in plasma levels of Example 1 compared to Nabumetone.
  • a “therapeutically effective amount” is an amount necessary to prevent, delay or reduce the severity of inflammation and also includes an amount necessary to enhance normal physiological functioning.
  • a “pharmaceutically acceptable” component (such as a salt, carrier, excipient or diluent) of a formulation according to the present invention is a component which (1) is compatible with the other ingredients of the formulation in that it can be combined with the 6MNA prodrugs of the present invention without eliminating the biological activity of the 6MNA prodrugs; and (2) is suitable for use with an animal (e.g., a human) without undue adverse side effects, such as toxicity, irritation, and allergic response. Side effects are “undue” when their risk outweighs the benefit provided by the pharmaceutical composition.
  • the pharmaceutical composition is wherein R is selected from the group consisting of is H and COR′ wherein R′ is selected from the group consisting of C, to C 6 alkyl, (CH 2 ) m O(CH 2 ) n , (CH 2 ) m (OC 2 H 4 ) p O(CH 2 ) n , (CH 2 ) m ( 0 C 2 H 4 ) p , (OCH 2 H 4 ) p ONO 2 and (OCH 2 H 4 ) p O(CH 2 ) n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4.
  • R is H, and such composition converts directly to the active drug 6MNA.
  • R is a therapeutic moiety such as
  • Such prodrug composition can advantageously be used to treat inflammation, and also provide analgesic and antipyretic properties.
  • 6MNA prodrugs of the present invention may optionally be administered in conjunction with other compounds useful in the treatment of inflammation or useful in treatment of other indications associated with inflammation such as pain.
  • the other compounds may optionally be administered concurrently.
  • concurrently means sufficiently close in time to produce a combined effect (that is, concurrently may be simultaneously, or it may be two or more events occurring within a short time period before or after each other).
  • the administration of two or more compounds “in combination” means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other.
  • the two compounds may be administered simultaneously (i.e., concurrently) or sequentially.
  • Simultaneous administration may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
  • the present invention is primarily concerned with the treatment of human subjects, but the invention may also be carried out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes.
  • the 6MNA prodrugs disclosed herein can, as noted above, be prepared in the form of their pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; (b) salts formed from elemental anions such as chlorine, bromine, and iodine, and (c) salts derived from bases, such as ammonium salts, alkali metal
  • the 6MNA prodrugs described above may be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (9 th Ed. 1995).
  • the prodrug (including the physiologically acceptable salts thereof) is typically admixed with, inter alla, an acceptable carrier.
  • the carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient.
  • the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the 6MNA prodrug.
  • One or more 6MNA prodrugs may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.
  • compositions of the invention include those suitable for oral, rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (i.e., both skin and mucosal surfaces, including airway surfaces) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular 6MNA prodrug which is being used.
  • Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tables, each containing a predetermined amount of the 6MNA prodrug; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the 6MNA prodrug and a suitable carrier (which may contain one or more accessory ingredients as noted above).
  • the formulations of the invention are prepared by uniformly and intimately admixing the 6MNA prodrug with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture.
  • a tablet may be prepared by compressing or molding a powder or granules containing the 6MNA prodrug, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s).
  • Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.
  • Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the 6MNA prodrug in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
  • Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the 6MNA prodrug, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient.
  • Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents.
  • the formulations may be presented in unit ⁇ dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use.
  • sterile liquid carrier for example, saline or water-for-injection immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • an injectable, stable, sterile composition comprising a compound of Formula (I), or a salt thereof, in a unit dosage form in a sealed container.
  • the compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject.
  • the unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt.
  • a sufficient amount of emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier.
  • emulsifying agent is phosphatidyl choline.
  • Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the 6MNA prodrug with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
  • Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.
  • Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6): 318 (1986)) and typically take the form of an optionally buffered aqueous solution of the 6MNA prodrug. Suitable formulations comprise citrate or bis ⁇ tris buffer (pH6) or ethanol/water and contain from 0.1 to 0.2M active ingredient.
  • any 6MNA prodrug will vary somewhat from compound to compound, and patient to patient, and will depend upon factors such as the age and condition of the patient and the route of delivery. Such dosages can be determined in accordance with routine pharmacological procedures known to those skilled in the art.
  • the therapeutically effective dosage of any specific compound will vary somewhat from compound to compound, and patient to patient, and will depend upon the condition of the patient and the route of delivery.
  • a dosage from about 0.1 to about 50 mg/kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the 6MNA prodrug, including the cases where a salt is employed.
  • Toxicity concerns at the higher level may restrict intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon the weight of the active base, including the cases where a salt is employed.
  • a dosage from about 10 mg/kg to about 50 mg/kg may be employed for oral administration.
  • a dosage from about 0.5 mg/kg to 5 mg/kg may be employed for intramuscular injection.
  • the duration of the treatment is usually once per day for a period of two to three weeks or until the condition is essentially controlled. Lower doses given less frequently can be used prophylactically to prevent or reduce the incidence of recurrence of the infection.
  • 6-MNA (1 g, 0.0046 mol) was suspended in anhydrous THF and was cooled with ice bath suspension BH3(1 M solution in THF, 5 ml) was added. The reaction mixture was stirred for 3 hours then DI water and sodium carbonate added. THF was removed and aqueous phase extracted with ethyl acetate then washed with water, dried over. Na2SO4, filtered concentrated and dried via vacuum.
  • Example 1 had a rat paw edema, % inhibition of 67.5 as compared to 60.0 for Nabumetone.
  • FIG. 1 shows higher plasma levels, with more rapid onset, are achieved with Example 1 as compared to Nabumetone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides therapeutically effective amounts of 6MNA prodrugs. The pharmaceutical composition comprises
Figure US20050054735A1-20050310-C00001
wherein R is H or COR′, wherein R′ is selected from the group consisting of C1 to C6 alkyl, (CH2)m O(CH2)n, (CH2)m(OC2H4)p O(CH2)n, (CH2)m(OC2H4)p, (OCH2H4)p ONO2 and (OCH2H4)p O(CH2)n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.

Description

    RELATED APPLICATION
  • The present application is a continuation of U.S. application Ser. No. 09/697,795, filed Oct. 27, 2000, which claims priority from U.S. Provisional Application 60/161,864, filed Oct. 27, 1999, the disclosures of which are incorporated by reference herein in their entireties.
    • FIELD AND BACKGROUND OF THE INVENTION
  • The present invention relates to pharmaceutical compositions useful for treatment of inflammation in humans utilizing compounds that are prodrugs of 6-methoxy-2-naphthylacetic acid (hereinafter “6MNA”).
  • Various naphthalene derivatives are known to be useful for the treatment of inflammation and for various rheumatic and arthritic conditions. For example, Naproxen having the formula (I):
    Figure US20050054735A1-20050310-C00002
    as described in U.S. Pat. No. 4,009,197 to Fried et al. Compound (I) can, however, cause severe irritation of the gastronintestinal tract at dosages only slightly greater than the excess of the therapeutic dose.
  • Another naphthalene derivative is nabumetone having the formula (II):
    Figure US20050054735A1-20050310-C00003
    as described in U.S. Pat. Nos. 4,061,779 and 4,420,639 to Lake et al. Nabumetone works by inhibiting cyclooxygenase, an enzyme responsible for making prostaglandins which are mediators of inflammation. Nabumetone is a prodrug which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid, Formula (III):
    Figure US20050054735A1-20050310-C00004
    (See Haddock, R. E. et al; Metabolism of Nabumetone (BRL 14777 by various species including man,” Xenobiotica; 14(4): 327-337 (1984)). Nabumetone is commercially available as Relafen® from Smithkline Beecham, Inc. However, only about 35 percent of orally administered nabumetone is transferred in vivo into 6MNA.
  • It is therefore an object of the present invention to provide 6MNA prodrugs which are more readily transformed into 6MNA than nabumetone. It is believed that improvement in the body's ability to hydrolyze and solubilize the prodrug can contribute to this transformation. Thus, it is another object to improve the hydrolysis and solubility of the prodrug to provide better transformation to 6MNA.
  • Another concern with 6MNA and its related prodrugs is that the presence of the carboxylic acid moiety can cause stomach irritation and/or ulceration. Thus, it is another object of the present invention that provides prodrugs of 6MNA having a reduced propensity to cause stomach irritation.
    • SUMMARY OF THE INVENTION
  • As discussed above, the present invention provides therapeutically effective amounts of 6MNA prodrugs. It is believed that the 6MNA prodrug of the invention has improved hydrolysis and solubility. It is believed that the prodrugs of the invention are useful for the treatment of inflammation in humans, and can provide analgesic and antipyretic properties.
  • The pharmaceutical composition comprises
    Figure US20050054735A1-20050310-C00005
    wherein R is selected from the group consisting of H and COR′, wherein R′ is selected from the group consisting of C1 to C6 alkyl, (CH2)m O(CH2)n, (CH2)m(OC2H4)p O(CH2)n, (CH2)m(OC2H4)p, (OCH2H4)p ONO2 and (OCH2H4)p O(CH2)n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.
  • The foregoing and other aspects of the present invention are explained in detail in the detailed description and example set forth below.
    • BRIEF DESCRIPTION OF THE FIGURE
  • FIG. 1 is a graph of in plasma levels of Example 1 compared to Nabumetone.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention will now be described more fully hereinafter. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
  • The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
  • Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
  • A “therapeutically effective amount” is an amount necessary to prevent, delay or reduce the severity of inflammation and also includes an amount necessary to enhance normal physiological functioning.
  • As used herein, a “pharmaceutically acceptable” component (such as a salt, carrier, excipient or diluent) of a formulation according to the present invention is a component which (1) is compatible with the other ingredients of the formulation in that it can be combined with the 6MNA prodrugs of the present invention without eliminating the biological activity of the 6MNA prodrugs; and (2) is suitable for use with an animal (e.g., a human) without undue adverse side effects, such as toxicity, irritation, and allergic response. Side effects are “undue” when their risk outweighs the benefit provided by the pharmaceutical composition.
  • In one embodiment, the pharmaceutical composition is
    Figure US20050054735A1-20050310-C00006
    wherein R is selected from the group consisting of is H and COR′ wherein R′ is selected from the group consisting of C, to C6 alkyl, (CH2)m O(CH2)n, (CH2)m(OC2H4)p O(CH2)n, (CH2)m(0C2H4)p, (OCH2H4)p ONO2 and (OCH2H4)p O(CH2)n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4.
  • In a preferred embodiment R is H, and such composition converts directly to the active drug 6MNA.
  • In another embodiment, R is a therapeutic moiety such as
    Figure US20050054735A1-20050310-C00007
  • Such prodrug composition can advantageously be used to treat inflammation, and also provide analgesic and antipyretic properties. 6MNA prodrugs of the present invention may optionally be administered in conjunction with other compounds useful in the treatment of inflammation or useful in treatment of other indications associated with inflammation such as pain. The other compounds may optionally be administered concurrently. As used herein, the word “concurrently” means sufficiently close in time to produce a combined effect (that is, concurrently may be simultaneously, or it may be two or more events occurring within a short time period before or after each other).
  • As used herein, the administration of two or more compounds “in combination” means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other. The two compounds may be administered simultaneously (i.e., concurrently) or sequentially. Simultaneous administration may be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
  • The phrases “concurrent administration,” “administration in combination,” “simultaneous administration” or “administered simultaneously” as used herein, interchangeably mean that the compounds are administered at the same point in time or immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.
  • The present invention is primarily concerned with the treatment of human subjects, but the invention may also be carried out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes.
  • The 6MNA prodrugs disclosed herein can, as noted above, be prepared in the form of their pharmaceutically acceptable salts. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; (b) salts formed from elemental anions such as chlorine, bromine, and iodine, and (c) salts derived from bases, such as ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium, and salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine.
  • The 6MNA prodrugs described above may be formulated for administration in a pharmaceutical carrier in accordance with known techniques. See, e.g., Remington, The Science And Practice of Pharmacy (9th Ed. 1995). In the manufacture of a pharmaceutical formulation according to the invention, the prodrug (including the physiologically acceptable salts thereof) is typically admixed with, inter alla, an acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.01 or 0.5% to 95% or 99% by weight of the 6MNA prodrug. One or more 6MNA prodrugs may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.
  • The formulations of the invention include those suitable for oral, rectal, topical, buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous), topical (i.e., both skin and mucosal surfaces, including airway surfaces) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular 6MNA prodrug which is being used.
  • Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tables, each containing a predetermined amount of the 6MNA prodrug; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the 6MNA prodrug and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the 6MNA prodrug with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the 6MNA prodrug, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.
  • Formulations suitable for buccal (sub-lingual) administration include lozenges comprising the 6MNA prodrug in a flavoured base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
  • Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the 6MNA prodrug, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient. Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents. The formulations may be presented in unit\dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. For example, in one aspect of the present invention, there is provided an injectable, stable, sterile composition comprising a compound of Formula (I), or a salt thereof, in a unit dosage form in a sealed container. The compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject. The unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt. When the compound or salt is substantially water-insoluble, a sufficient amount of emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier. One such useful emulsifying agent is phosphatidyl choline.
  • Formulations suitable for rectal administration are preferably presented as unit dose suppositories. These may be prepared by admixing the 6MNA prodrug with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
  • Formulations suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.
  • Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6): 318 (1986)) and typically take the form of an optionally buffered aqueous solution of the 6MNA prodrug. Suitable formulations comprise citrate or bis\tris buffer (pH6) or ethanol/water and contain from 0.1 to 0.2M active ingredient.
  • The therapeutically effective dosage of any 6MNA prodrug, the use of which is in the scope of present invention, will vary somewhat from compound to compound, and patient to patient, and will depend upon factors such as the age and condition of the patient and the route of delivery. Such dosages can be determined in accordance with routine pharmacological procedures known to those skilled in the art.
  • The therapeutically effective dosage of any specific compound, the use of which is in the scope of present invention, will vary somewhat from compound to compound, and patient to patient, and will depend upon the condition of the patient and the route of delivery. As a general proposition, a dosage from about 0.1 to about 50 mg/kg will have therapeutic efficacy, with all weights being calculated based upon the weight of the 6MNA prodrug, including the cases where a salt is employed. Toxicity concerns at the higher level may restrict intravenous dosages to a lower level such as up to about 10 mg/kg, with all weights being calculated based upon the weight of the active base, including the cases where a salt is employed. A dosage from about 10 mg/kg to about 50 mg/kg may be employed for oral administration. Typically, a dosage from about 0.5 mg/kg to 5 mg/kg may be employed for intramuscular injection. The duration of the treatment is usually once per day for a period of two to three weeks or until the condition is essentially controlled. Lower doses given less frequently can be used prophylactically to prevent or reduce the incidence of recurrence of the infection.
    • EXAMPLE Example 1 Synthesis of 2-(6-Methoxy-naphthalen-2-yl)-ethanol
  • 6-MNA (1 g, 0.0046 mol) was suspended in anhydrous THF and was cooled with ice bath suspension BH3(1 M solution in THF, 5 ml) was added. The reaction mixture was stirred for 3 hours then DI water and sodium carbonate added. THF was removed and aqueous phase extracted with ethyl acetate then washed with water, dried over. Na2SO4, filtered concentrated and dried via vacuum.
  • Yield 93%. Melting point 110-113° C. product was analyzed by elemental analysis, IR, MS, NMR.
  • MS: 202.10
  • IR (cm−1)
  • Elemental analysis: C 56.18; H 4.28; N 4.03
  • NMR 1H
  • Analysis of blood samples in rats after oral delivery showed a conversion of the compound of Example 1 to the active drug 6MNA. Example 1 had a rat paw edema, % inhibition of 67.5 as compared to 60.0 for Nabumetone. FIG. 1 shows higher plasma levels, with more rapid onset, are achieved with Example 1 as compared to Nabumetone.
  • Analysis of blood samples in rats after oral delivery showed a conversion of the compound of Example 1 to the active drug 6MNA.
  • The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

Claims (2)

1. A pharmaceutical composition useful for treatment of inflammation to humans comprising a therapeutically effective amount of a compound of the formula:
Figure US20050054735A1-20050310-C00008
wherein R is a therapeutic moiety.
2. A method of treating inflammation comprising administering a therapeutically effective amount of a compound of the formula:
Figure US20050054735A1-20050310-C00009
wherein R is a therapeutic moiety.
US10/970,571 1999-10-27 2004-10-21 6-Methoxy-2-naphthylacetic acid prodrugs Abandoned US20050054735A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/970,571 US20050054735A1 (en) 1999-10-27 2004-10-21 6-Methoxy-2-naphthylacetic acid prodrugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16186499P 1999-10-27 1999-10-27
US09/697,795 US6525098B1 (en) 1999-10-27 2000-10-27 6-methoxy-2-naphthylacetic acid prodrugs
US10/170,800 US20030069309A1 (en) 1999-10-27 2002-06-12 6-Methoxy-2-naphthylacetic acid prodrugs
US10/970,571 US20050054735A1 (en) 1999-10-27 2004-10-21 6-Methoxy-2-naphthylacetic acid prodrugs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/170,800 Continuation US20030069309A1 (en) 1999-10-27 2002-06-12 6-Methoxy-2-naphthylacetic acid prodrugs

Publications (1)

Publication Number Publication Date
US20050054735A1 true US20050054735A1 (en) 2005-03-10

Family

ID=22583099

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/697,795 Expired - Fee Related US6525098B1 (en) 1999-10-27 2000-10-27 6-methoxy-2-naphthylacetic acid prodrugs
US10/170,800 Abandoned US20030069309A1 (en) 1999-10-27 2002-06-12 6-Methoxy-2-naphthylacetic acid prodrugs
US10/970,571 Abandoned US20050054735A1 (en) 1999-10-27 2004-10-21 6-Methoxy-2-naphthylacetic acid prodrugs

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/697,795 Expired - Fee Related US6525098B1 (en) 1999-10-27 2000-10-27 6-methoxy-2-naphthylacetic acid prodrugs
US10/170,800 Abandoned US20030069309A1 (en) 1999-10-27 2002-06-12 6-Methoxy-2-naphthylacetic acid prodrugs

Country Status (20)

Country Link
US (3) US6525098B1 (en)
EP (2) EP1223926A2 (en)
JP (2) JP2003512424A (en)
KR (2) KR20020043248A (en)
CN (2) CN1413108A (en)
AU (2) AU1576101A (en)
BR (2) BR0015121A (en)
CA (2) CA2389181A1 (en)
CZ (2) CZ20021435A3 (en)
HK (2) HK1048256A1 (en)
HU (2) HUP0203321A2 (en)
IL (2) IL149257A0 (en)
MX (2) MXPA02004355A (en)
NO (2) NO20022000L (en)
NZ (2) NZ518554A (en)
PL (2) PL354895A1 (en)
RU (2) RU2002113657A (en)
TW (1) TWI262791B (en)
WO (2) WO2001030338A2 (en)
ZA (2) ZA200203229B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262791B (en) * 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2493156A1 (en) * 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US8062653B2 (en) 2009-02-18 2011-11-22 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
EP2398761A4 (en) * 2009-02-18 2015-11-04 Bezwada Biomedical Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
JP2012522796A (en) * 2009-04-02 2012-09-27 アラーガン インコーポレイテッド Prostaglandin E receptor antagonist
CN101928227A (en) * 2009-12-16 2010-12-29 天津工业大学 Mutual prodrug of 6-methoxyl-2-naphthylacetic acid and salicylanilide compounds, preparation method and application thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009197A (en) 1967-01-13 1977-02-22 Syntex Corporation 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof
US3904682A (en) * 1967-01-13 1975-09-09 Syntex Corp 2-(6{40 -Methoxy-2{40 -naphthyl)acetic acid
JPS5441587B1 (en) * 1969-09-30 1979-12-08 Syntex Corp
DE2051012A1 (en) * 1970-10-17 1972-04-20 Syntex Corp., Panama 1,6-methano-(10)-annulenes - with anti-inflammatory analgesic antipyr hypocholesterolaemic and fibrinolytic activity
US3978116A (en) * 1971-11-04 1976-08-31 Syntex Corporation 2-naphthyl acetic acid derivatives and compositions and methods thereof
US3883662A (en) * 1973-03-29 1975-05-13 Syntex Corp Method for delaying the onset of, or postponing, parturition
US4327022A (en) * 1973-08-16 1982-04-27 Sterling Drug Inc. Heterocyclic alkyl naphthols
US4061779A (en) 1973-09-11 1977-12-06 Beecham Group Limited Naphthalene derivatives having anti-inflammatory activity
US4420639C1 (en) 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
DE2860631D1 (en) 1978-01-07 1981-05-07 Beecham Group Plc Process for the preparation of 4-(6-methoxy-2-naphthyl)butan-2-one and 2-acetyl-3-(6-methoxy-2-naphthyl) propenoic acid esters
US4246193A (en) 1979-11-26 1981-01-20 Syntex Corporation Process for the resolution of d,1 2-(6-methoxy-2-naphthyl)propionic acid
CH641432A5 (en) 1978-07-19 1984-02-29 Syntex Pharma Int METHOD FOR SPLITTING RACEMIC 6-METHOXY-ALPHA-METHYL-2-NAPHTHALINE ACID INTO THE OPTICAL ANTIPODES.
EP0011279B1 (en) 1978-11-14 1982-05-05 Sagami Chemical Research Center Process for the preparation of aromatically substituted acetic acids
DE2963747D1 (en) * 1978-11-23 1982-11-04 Beecham Group Plc Naphthalene derivatives, a process for their preparation and their use in anti-inflammatory pharmaceutical compositions
IT1109200B (en) 1979-02-20 1985-12-16 Montedison Spa PROCESS FOR THE PREPARATION OF ARYLACETIC ACID ESTERS FROM ALPHA-ALO-ALCHYLARYL KETONES
US4515811A (en) 1979-07-06 1985-05-07 Syntex Corporation Process for the resolution of d,1 2-(6-methoxy-2-naphthyl)propionic acid
IT1168387B (en) 1981-04-01 1987-05-20 Alfa Farmaceutici Spa PROCEDURE FOR THE PREPARATION OF 2- (6-METHOXY-2-NAFTIL) -PROPIONIC ACID
US4542237A (en) 1981-04-30 1985-09-17 Syntex Pharmaceuticals International Limited Manufacture of alpha-arylalkanoic acids and precursors
US4654438A (en) 1981-04-30 1987-03-31 Syntex Pharmaceuticals International Limited Manufacture of alpha-arylalkanoic acids and precursors
IT1190741B (en) 1982-03-22 1988-02-24 Blaschim Spa PROCEDURE FOR PREPARING ACID ESTERS 2- (6'-METHOXY-2'-NAFTIL) -PROPIONIC
IT1210947B (en) 1982-11-03 1989-09-29 Zambon Spa PROCEDURE FOR PREPARING ARILALCANOIC ACID ESTERS
US4723033A (en) 1982-11-24 1988-02-02 Syntex Pharmaceuticals International Ltd. Manufacture of optically active α-arylalkanoic acids and precursors thereof
IL67445A (en) 1982-12-09 1985-11-29 Teva Pharma Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids
IT1164319B (en) 1983-07-27 1987-04-08 Blaschim Spa ACID RESOLUTION PROCEDURE (+ -) 2- (6'-METHOXY-2'-NAFTIL) -PROPIONIC
JPS6081145A (en) 1983-10-11 1985-05-09 Nissan Chem Ind Ltd Production of d-alpha-(6-methoxy-2-naphthyl)propionic acid by hydrolysis of d-alpha-(6-methoxy-2-naphthyl)propionic acid ester with alkali
US4661525A (en) 1984-03-28 1987-04-28 Texaco Inc. Process for producing lower aliphatic alcohols
GB8416638D0 (en) 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
ES8700649A1 (en) 1984-07-11 1986-11-16 Blaschim Spa Process for the preparation of arylalkanoic acids by oxidative rearrangement of arylalkanones
US4670586A (en) 1984-09-12 1987-06-02 Nippon Chemicals Co., Ltd. Method for the production of α-aryl-alkanoic acid
DE3584754D1 (en) 1984-09-24 1992-01-09 Nobel Chemicals Ab METHOD FOR PRODUCING ARYLALKYLKETONES.
IT1183626B (en) 1985-05-14 1987-10-22 Vamp Srl POLYOLEFINE SELF-EXTINGUISHING POLYMER PRODUCTS
IT1201443B (en) 1985-07-31 1989-02-02 Zambon Spa INTERMEDIATES FOR THE SYNTHESIS OF CARBOXYLIC ACIDS
CA1286316C (en) 1986-02-08 1991-07-16 Isoo Shimizu Method for refining 2-(aryl substituted)-propionic acid or its salt
JPH064561B2 (en) 1986-02-08 1994-01-19 日本石油化学株式会社 Method for producing (substituted aryl) carboxylic acid
IT1197800B (en) 1986-08-01 1988-12-06 Zambon Spa CARBOXYLIC ACID SYNTHESIS PROCESS
IT1198234B (en) 1986-12-23 1988-12-21 Zambon Spa STEREOCONVERGENT PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CARBOXYLIC ACIDS
US5202495A (en) 1987-03-26 1993-04-13 Callander Sidney E Chemical process
IT1222013B (en) 1987-07-10 1990-08-31 Chimica Profarmaco Spa Ind OPTIC RESOLUTION PROCESS OF PROPIONIC ACID 2 (6 METHOXES 2 NAFTIL)
US5225603A (en) 1987-07-14 1993-07-06 Hoechst Celanese Corporation Preparation of 4-(6'-methoxy-2'-naphthyl)-3-buten-2-one
JP2518014B2 (en) 1988-05-31 1996-07-24 日産化学工業株式会社 Method for purifying α-substituted acetic acid
GB8915104D0 (en) 1989-06-30 1989-08-23 Beecham Group Plc Chemical process
NL9001703A (en) 1990-07-27 1992-02-17 Westspur Investment Ltd PROCESS FOR THE PREPARATION OF S (+) - 6-METHOXY-ALFA-METHYL-2-Naphthalene-ACETIC ACID.
KR930003864B1 (en) 1990-10-19 1993-05-14 한국과학기술연구원 Process for producing d-2-(6-methoxy-2-naphthyl)-propionic acid
US5179208A (en) 1990-10-19 1993-01-12 Korea Institute Of Science And Technology Process for preparing d-2-(6-methoxy-2-naphthyl)-propionic acid and intermediate thereof
DK0525506T4 (en) 1991-07-31 1999-10-11 Tessenderlo Chem Nv Process for alpha monoalkylation of aryl acetonitriles, aryl aceto esters and aryl acetic acids
US5248815A (en) 1991-12-27 1993-09-28 Paradies Henrich H Stereo-selective synthesis of 2-aryl-propionic acids of high optical purity by using chiral oxazolines
GB9201857D0 (en) 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
FR2686876B1 (en) 1992-02-04 1994-05-13 Hoechst Ste Francaise PROCESS FOR THE PREPARATION OF ARYLACETIC ACIDS AND THEIR SALTS OF ALKALINE METALS.
IT1256345B (en) 1992-08-20 1995-12-01 NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
IT1256450B (en) 1992-11-26 1995-12-05 Soldato Piero Del NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
US5223640A (en) 1992-12-23 1993-06-29 Hoechst Celanese Corporation Preparation of optically active α-aryl propionic acids
GB9314693D0 (en) 1993-07-15 1993-08-25 Smithkline Beecham Plc Naphthyl derivatives for treatment method
AU678063B2 (en) 1993-10-06 1997-05-15 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
DK0759899T3 (en) 1994-05-10 1999-12-20 Nicox Sa Nitro compounds and their compositions with anti-inflammatory, analgesic and antithrombotic activities
US5426243A (en) 1994-08-17 1995-06-20 Albemarle Corporation Process for preparing 1,6-dibromo-2-naphthylene compounds
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5600009A (en) 1996-04-09 1997-02-04 Hoechst Celanese Corporation Use of 4-substituted 2-butanones to prepare nabumetone
US5750764A (en) 1995-11-17 1998-05-12 Aeci Limited Synthesis and resolution of propionic acid derivatives
IT1285567B1 (en) 1996-02-21 1998-06-18 Alfa Chem Ital NEW PROCESS FOR THE SYNTHESIS OF NABUMETONE
IT1282686B1 (en) 1996-02-26 1998-03-31 Nicox Sa COMPOUNDS ABLE TO REDUCE DRUG TOXICITY
IT1283638B1 (en) 1996-07-29 1998-04-23 Archimica Spa PROCEDURE FOR THE PREPARATION OF A NAFTILBUTANONE
US5756851A (en) 1996-10-21 1998-05-26 Albemarle Corporation Production of nabumetone or precursors thereof
US5792886A (en) 1997-01-08 1998-08-11 Albemarle Corporation Production of racemic 2-(6-methoxy-2-naphthyl) propionic acid of precursors thereof
US5741938A (en) 1997-02-21 1998-04-21 Albemarle Corporation Production of alkyl aralkyl keones from allylic-aralkenyl secondary alcohols
AU6229698A (en) * 1997-02-21 1998-09-09 Takeda Chemical Industries Ltd. Fused ring compounds, process for producing the same and use thereof
US5847225A (en) 1997-04-25 1998-12-08 Albemarle Corporation Production of naphthyl-substituted ketones from naphthaldehydes
IT1291284B1 (en) 1997-04-30 1999-01-07 Secifarma Spa PROCESS FOR THE PREPARATION OF 4- (6'-METHOXY-2'-NAFTIL) BUTAN-2-ONE (NABUMETONE).
US5861538A (en) 1997-08-04 1999-01-19 Albemarle Corporation Production of alkoxynaphthyl-substituted ketones from naphthaldehydes
US5874614A (en) 1997-12-11 1999-02-23 Albemarle Corporation Sodium (S)-2-(6-methoxy-2-naphthyl)propionate monohydrate
US6552078B2 (en) * 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) * 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) * 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs

Also Published As

Publication number Publication date
EP1223922A2 (en) 2002-07-24
NO20022000D0 (en) 2002-04-26
NO20022001D0 (en) 2002-04-26
HK1048256A1 (en) 2003-03-28
AU2919601A (en) 2001-05-08
HUP0203790A2 (en) 2003-04-28
NZ518554A (en) 2004-05-28
CZ20021433A3 (en) 2002-08-14
IL149258A0 (en) 2002-11-10
CA2387098A1 (en) 2001-05-03
IL149257A0 (en) 2002-11-10
TWI262791B (en) 2006-10-01
HK1048257A1 (en) 2003-03-28
EP1223926A2 (en) 2002-07-24
NZ518553A (en) 2004-02-27
HUP0203790A3 (en) 2003-05-28
WO2001030338A8 (en) 2002-11-21
WO2001030338A3 (en) 2002-01-31
US6525098B1 (en) 2003-02-25
KR20020043248A (en) 2002-06-08
WO2001030338A2 (en) 2001-05-03
CZ20021435A3 (en) 2002-08-14
HUP0203321A2 (en) 2003-02-28
NO20022000L (en) 2002-06-27
WO2001030334A3 (en) 2002-03-21
ZA200203231B (en) 2003-07-23
BR0015121A (en) 2002-07-02
HU0203790D0 (en) 2002-12-28
WO2001030334A2 (en) 2001-05-03
BR0015122A (en) 2002-07-09
CA2389181A1 (en) 2001-05-03
MXPA02004357A (en) 2002-11-07
JP2003512424A (en) 2003-04-02
AU1576101A (en) 2001-05-08
CN1413106A (en) 2003-04-23
JP2003512425A (en) 2003-04-02
US20030069309A1 (en) 2003-04-10
KR20020043249A (en) 2002-06-08
CN1413108A (en) 2003-04-23
RU2002113657A (en) 2004-01-10
ZA200203229B (en) 2003-07-23
PL354895A1 (en) 2004-03-22
RU2002113661A (en) 2004-01-10
MXPA02004355A (en) 2002-11-07
NO20022001L (en) 2002-06-25
PL354510A1 (en) 2004-01-26

Similar Documents

Publication Publication Date Title
US8569536B2 (en) C-nitroso-derived nitroxyl donors
US20190152991A1 (en) Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
EP1239855A2 (en) Method for the prevention and/or treatment of atherosclerosis
US6525098B1 (en) 6-methoxy-2-naphthylacetic acid prodrugs
US6610739B2 (en) 6-methoxy-2-naphthylacetic acid prodrugs
JP2005514352A6 (en) Treatment of autoimmune diseases
US6730701B2 (en) 6-methoxy-2-naphthylacetic acid prodrugs
US6340696B1 (en) Viral treatment
AU2006200877A1 (en) 6-Methoxy-2-Naphthylacetic Acid Prodrugs
JPS60158149A (en) Antiinflammatory 1,4-naphthoquinone derivative
FR2569563A1 (en) Formulation based on benzoylecgonine or benzoylnorecgonine for the treatment of arthritis

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOBEX CORPORATION, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EKWURIBE, NNOCHIRI N.;DYAKONOV, TATYANA;REEL/FRAME:015971/0918;SIGNING DATES FROM 20050330 TO 20050408

AS Assignment

Owner name: BIOCON LIMITED,INDIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:NOBEX CORPORATION;REEL/FRAME:017649/0280

Effective date: 20051201

Owner name: BIOCON LIMITED, INDIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:NOBEX CORPORATION;REEL/FRAME:017649/0280

Effective date: 20051201

AS Assignment

Owner name: BIOCON LIMITED,INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOBEX CORPORATION;REEL/FRAME:017555/0904

Effective date: 20060417

Owner name: BIOCON LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOBEX CORPORATION;REEL/FRAME:017555/0904

Effective date: 20060417

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION